Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methotrexate (low dose) Clear all
Completed Not applicable Interventional Results available

Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)

NCT02786134
View directory record Official record
Conditions
Coronary Heart Disease, Metabolic Syndrome, Diabetes Mellitus
Interventions
PET scan, Echocardiogram
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT00381680
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
vincristine sulfate, prednisone, doxorubicin hydrochloride, pegaspargase, cytarabine, methotrexate, dexamethasone, etoposide, cyclophosphamide, leucovorin calcium, filgrastim, asparaginase, mercaptopurine
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
159
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT00408005
View directory record Official record
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
191
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 20, 2026, 6:37 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

NCT00136084
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
8
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990
View directory record Official record
Conditions
Lymphoma
Interventions
Regimen A, Regimen B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

NCT00000658
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 20, 2026, 6:37 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Not applicable Interventional

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Treatment Acceleration, Monthly Assessment
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 1 Interventional

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

NCT00496665
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Vandetanib, Cyclophosphamide, Methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

NCT00928018
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 20, 2026, 6:37 AM EDT
Not yet recruiting Phase 3 Interventional

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

NCT07291102
View directory record Official record
Conditions
Medulloblastoma
Interventions
Bridging Chemotherapy, Induction Cycles A1-A3, Induction Cycles A4-5, Consolidation Cycle A6, HIT-SKK Chemotherapy Cycles B1-3, Modified HIT-SKK Cycle B4-5
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 5 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

NCT00083031
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, cyclophosphamide, methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

NCT01949116
View directory record Official record
Conditions
HIV Infections
Interventions
LDMTX, Placebo, Folic acid
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 20, 2026, 6:37 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tulisokibart, Placebo, Methotrexate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Not applicable Interventional

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

NCT00905073
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
cyclosporin and methotrexate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
8 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 1994
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Sep 20, 2026, 6:37 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

NCT01389076
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bexxar, Low Dose Methotrexate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 4 Interventional Results available

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

NCT03635957
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 20, 2026, 6:37 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

NCT01554696
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
peficitinib, Placebo, methotrexate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 20, 2026, 6:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

NCT05600426
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Drug · Procedure · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 20, 2026, 6:37 AM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 20, 2026, 6:37 AM EDT